2021 Metabolic Partnering Global Report - In-depth Understanding of Metabolic Deal Trends Since 2014
Dublin, Dec. 23, 2021 (GLOBE NEWSWIRE) -- The "Global Metabolic Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Metabolic Partnering 2014 to 2021 provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
Trends in Metabolic partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Metabolic partnering agreement structure
Metabolic partnering contract documents
Top Metabolic deals by value
Most active Metabolic dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.
The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scope
Global Metabolic Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.
Global Metabolic Partnering 2014 to 2021 includes:
Trends in Metabolic dealmaking in the biopharma industry since 2014
Access to headline, upfront, milestone and royalty data
Access to hundreds of Metabolic deal contract documents
Comprehensive access to over 1100 Metabolic deal records
The leading Metabolic deals by value since 2014
Most active Metabolic dealmakers since 2014
The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.
In Global Metabolic Partnering 2014 to 2021, available deals and contracts are listed by:
Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Metabolic Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1100 metabolic deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Global Metabolic Partnering 2014 to 2021 provides the reader with the following key benefits:
In-depth understanding of Metabolic deal trends since 2014
Access Metabolic deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Metabolic partner companies
Comprehensive access to over 1100 links to actual Metabolic deals entered into by the world's biopharma companies
In-depth review of Metabolic deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Metabolic opportunities
Uncover companies actively partnering Metabolic opportunities
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Metabolic dealmaking
2.1. Introduction
2.2. Metabolic partnering over the years
2.3. Metabolic partnering by deal type
2.4. Metabolic partnering by industry sector
2.5. Metabolic partnering by stage of development
2.6. Metabolic partnering by technology type
2.7. Metabolic partnering by therapeutic indication
Chapter 3 -Financial deal terms for Metabolic partnering
3.1. Introduction
3.2. Disclosed financials terms for Metabolic partnering
3.3. Metabolic partnering headline values
3.4. Metabolic deal upfront payments
3.5. Metabolic deal milestone payments
3.6. Metabolic royalty rates
Chapter 4 - Leading Metabolic deals and dealmakers
4.1. Introduction
4.2. Most active in Metabolic partnering
4.3. List of most active dealmakers in Metabolic
4.4. Top Metabolic deals by value
Chapter 5 - Metabolic contract document directory
5.1. Introduction
5.2. Metabolic partnering deals where contract document available
Chapter 6 - Metabolic dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Metabolic therapeutic target
Companies Mentioned
2XU
3SBio
5LINX
23andMe
A*STAR Agency for Science
Technology and Research
AB-Biotics
Abbott Laboratories
Abbvie
Abby Grace Foundation
Abeona Therapeutics
Abiogen Pharma
Academic Drug Discovery Consortium
Academy Medical
Acasti Pharma
Accord Healthcare
Acerus
Aceto Corporation
Acon Labs
Actavis (name changed to Allergan)
Activhealth
Acurian
Admera Health
Adocia
Advance Pharmaceutical
Adverum Biotechnologies
Aelan Cell Technologies
Aero Pump
AEterna Zentaris
Aetna
Aevi Genomic Medicine
Afimmune
AgaMatrix
AgBiome
Agilent Technologies
Aguettant
Ajinomoto
Akero Therapeutics
Akers Biosciences
AKSA Medical
Akston Biosciences
Albany Molecular Research
Albert Einstein College of Medicine
Albion
Albumedix
Alcon Laboratories
Alcresta
Alexion Pharmaceuticals
ALK-Abello
Allegro Ophthalmics
Allele Biotechnology and Pharmaceuticals
Allergan
AllerGenis
Alliance Pharma
All Star Health Brands
Alnylam Pharmaceuticals
ALR Technologies
Alteogen
Alzheimer's Association
Amarna Therapeutics
Amazentis
Ambrosia Nutraceuticals
Ambys Medicines
A Menarini Diagnostics
American Diabetes Association
American Gene Technologies
American Society for Parenteral and Enteral Nutrition
Amgen
Amicus Therapeutics
Amneal Pharmaceuticals
AMRA
Amunix
Amyris
Andromeda Biotech
AnGes MG
ANI Pharmaceuticals
Anji Pharma
Anokion
Antares Pharma
Antaros Medical
Antisense Therapeutics
AOP Orphan Pharmaceuticals
Apollo Endosurgery
Apollo Sugar
Apricus Biosciences
Arcadia Resources
ARCH Personalized Medicine Initiative
Arcturus Therapeutics
Arecor
argenx
Argon Medical Devices
Arix Bioscience
Arjuna Naturals
Arkray USA
Artizan Biosciences
Arzeda
Ascensia Diabetes Care
Ascletis
Aspect Biosystems
Aspen Holding
Astellas Pharma
AstraZeneca
AstraZeneca HealthCare Foundation
Attain Health
Atvio Biotech
Audentes Therapeutics
Australian Department of Health and Ageing
Australian Foundation for Diabetes Research
AutoGenomics
Autotelic
Avion Pharmaceuticals
Avivagen
Avrobio
Awamedica
AXIM Biotechnologies
Axxess Pharma
Aytu BioScience
Bambino Gesu Children's Hospital
Banting & Best Diabetes Centre (BBDC)
BASF
Baxter International
Bayer
Baylor College of Medicine
Beacon Discovery
Becton Dickinson
Beijing Sun-Novo Pharmaceutical Research
Benchworks
Bened Biomedical
Bertin Pharma
Best Choice
Beta-O2
Better Living Now
Beyond Type 1
BGN Technologies
BHV Pharmaceuticals
Bicycle Therapeutics
Bigfoot Biomedical
Bina Technologies
Bio-Rad Laboratories
BIOASTER
BioCision
Biocodex Microbiota Foundation
BIOCORP
Biodel
Biodelta Nutraceuticals
BioGaia
Biogen
Biohit
Bioinn Molecular Diagnosis
BiolineRX
Biomedical Catalyst Fund (UK)
BioMed X Innovation Center
BiopharmX
BioRestorative Therapies
Biosequel
BioTelemetry
BioViva Sciences
Bird Foundation
Blue Diamond Growers
Blue Mesa Health
BlueOcean Nutrascience
Boehringer Ingelheim
Bora Pharmaceuticals
Boston Scientific
Boston Therapeutics
Brigham and Women's Hospital
Bristol-Myers Squibb
Bruker
c-LEcta
For more information about this report visit https://www.researchandmarkets.com/r/mwnox5
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900